Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.

Sailer V, Eng KW, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E, Cyrta J, Rao R, Sahota S, Pauli C, Beg S, Motanagh S, Kossai M, Fontunge J, Puca L, Rennert H, Zhaoying Xiang J, Greco N, Kim R, MacDonald TY, McNary T, Blattner-Johnson M, Schiffman MH, Faltas BM, Greenfield JP, Rickman D, Andreopoulou E, Holcomb K, Vahdat LT, Scherr DS, van Besien K, Barbieri CE, Robinson BD, Fine HA, Ocean AJ, Molina A, Shah MA, Nanus DM, Pan Q, Demichelis F, Tagawa ST, Song W, Mosquera JM, Sboner A, Rubin MA, Elemento O, Beltran H.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00047. Epub 2019 Sep 20.

PMID:
31592503
2.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.

N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

PMID:
30786188
3.

Personalized Nutrition in Disrupting Cancer - Proceedings From the 2017 American College of Nutrition Annual Meeting.

Wallace TC, Bultman S, D'Adamo C, Daniel CR, Debelius J, Ho E, Eliassen H, Lemanne D, Mukherjee P, Seyfried TN, Tian Q, Vahdat LT.

J Am Coll Nutr. 2019 Jan;38(1):1-14. doi: 10.1080/07315724.2018.1500499. Epub 2018 Dec 4. Erratum in: J Am Coll Nutr. 2019 Sep-Oct;38(7):659.

PMID:
30511901
4.

A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.

Bao T, Seidman AD, Piulson L, Vertosick E, Chen X, Vickers AJ, Blinder VS, Zhi WI, Li Q, Vahdat LT, Dickler MN, Robson ME, Mao JJ.

Eur J Cancer. 2018 Sep;101:12-19. doi: 10.1016/j.ejca.2018.06.008. Epub 2018 Jul 13.

5.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.

6.

An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.

Walsh LA, Alvarez MJ, Sabio EY, Reyngold M, Makarov V, Mukherjee S, Lee KW, Desrichard A, Turcan Ş, Dalin MG, Rajasekhar VK, Chen S, Vahdat LT, Califano A, Chan TA.

Cell Rep. 2017 Aug 15;20(7):1623-1640. doi: 10.1016/j.celrep.2017.07.052.

7.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM.

Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.

8.

Sacituzumab govitecan: an antibody-drug conjugate.

Sahota S, Vahdat LT.

Expert Opin Biol Ther. 2017 Aug;17(8):1027-1031. doi: 10.1080/14712598.2017.1331214. Epub 2017 May 22. Review.

PMID:
28503956
9.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

10.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

11.

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K.

Oncologist. 2017 Mar;22(3):245-254. doi: 10.1634/theoncologist.2016-0265. Epub 2017 Feb 20.

12.

Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.

Sands S, Ladas EJ, Kelly KM, Weiner M, Lin M, Ndao DH, Dave A, Vahdat LT, Bender JG.

Support Care Cancer. 2017 Mar;25(3):701-708. doi: 10.1007/s00520-016-3441-6. Epub 2016 Nov 9.

13.

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D.

Nature. 2015 Nov 26;527(7579):472-6. doi: 10.1038/nature15748. Epub 2015 Nov 11.

14.

Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis.

Seo BR, Bhardwaj P, Choi S, Gonzalez J, Andresen Eguiluz RC, Wang K, Mohanan S, Morris PG, Du B, Zhou XK, Vahdat LT, Verma A, Elemento O, Hudis CA, Williams RM, Gourdon D, Dannenberg AJ, Fischbach C.

Sci Transl Med. 2015 Aug 19;7(301):301ra130. doi: 10.1126/scitranslmed.3010467.

15.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2015 Sep 1;21(17):3870-8. doi: 10.1158/1078-0432.CCR-14-3321. Epub 2015 May 5.

16.

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.

Stanton SE, Ward MM, Christos P, Sanford R, Lam C, Cobham MV, Donovan D, Scheff RJ, Cigler T, Moore A, Vahdat LT, Lane ME, Chuang E.

BMC Cancer. 2015 Apr 11;15:267. doi: 10.1186/s12885-015-1298-6.

17.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthorne T, Yellin MJ, Davis TA, Vahdat LT.

J Clin Oncol. 2015 May 10;33(14):1609-19. doi: 10.1200/JCO.2014.56.2959. Epub 2015 Apr 6.

PMID:
25847941
18.

Menopause is a determinant of breast adipose inflammation.

Iyengar NM, Morris PG, Zhou XK, Gucalp A, Giri D, Harbus MD, Falcone DJ, Krasne MD, Vahdat LT, Subbaramaiah K, Morrow M, Hudis CA, Dannenberg AJ.

Cancer Prev Res (Phila). 2015 May;8(5):349-58. doi: 10.1158/1940-6207.CAPR-14-0243. Epub 2015 Feb 26.

19.

Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients.

Ebenezer GJ, Carlson K, Donovan D, Cobham M, Chuang E, Moore A, Cigler T, Ward M, Lane ME, Ramnarain A, Vahdat LT, Polydefkis M.

Ann Clin Transl Neurol. 2014 Sep;1(9):639-49. doi: 10.1002/acn3.90. Epub 2014 Sep 2.

20.

Remodeling of the methylation landscape in breast cancer metastasis.

Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat LT, Lee W, Chan TA.

PLoS One. 2014 Aug 1;9(8):e103896. doi: 10.1371/journal.pone.0103896. eCollection 2014.

21.

New developments in metastatic breast cancer: integrating recent data into clinical practice.

Perez EA, Rugo HS, Vahdat LT.

Clin Adv Hematol Oncol. 2013;11(10 Suppl 16):1-18; quiz 19.

PMID:
24892840
22.

New developments in metastatic breast cancer: general discussion.

Vahdat LT, Rugo HS, Perez EA.

Clin Adv Hematol Oncol. 2013;11(10 Suppl 16):16-7. No abstract available.

PMID:
24765684
23.

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.

McIntyre K, O'Shaughnessy J, Schwartzberg L, Glück S, Berrak E, Song JX, Cox D, Vahdat LT.

Breast Cancer Res Treat. 2014 Jul;146(2):321-8. doi: 10.1007/s10549-014-2923-9. Epub 2014 Apr 4. Erratum in: Breast Cancer Res Treat. 2014 Jul;146(2):329.

24.

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.

Muss H, Cortes J, Vahdat LT, Cardoso F, Twelves C, Wanders J, Dutcus CE, Yang J, Seegobin S, O'Shaughnessy J.

Oncologist. 2014 Apr;19(4):318-27. doi: 10.1634/theoncologist.2013-0282. Epub 2014 Mar 28.

25.

Novel data in metastatic breast cancer.

Vahdat LT.

Clin Adv Hematol Oncol. 2013;11(10 Suppl 16):13-5. No abstract available.

PMID:
24637556
26.

Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.

Vahdat LT, Vrdoljak E, Gómez H, Li RK, Bosserman L, Sparano JA, Baselga J, Mukhopadhyay P, Valero V.

J Geriatr Oncol. 2013 Oct;4(4):346-52. doi: 10.1016/j.jgo.2013.07.006. Epub 2013 Aug 23.

PMID:
24472478
27.

Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.

Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, Kirby BJ, Giannakakou P.

Lab Chip. 2014 Jan 7;14(1):147-56. doi: 10.1039/c3lc51039e. Epub 2013 Nov 7.

28.

Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA.

Breast Cancer Res Treat. 2013 Oct;141(3):429-35. doi: 10.1007/s10549-013-2704-x. Epub 2013 Sep 26.

29.

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.

Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, Gopalakrishna P, Sparano JA.

Breast Cancer Res Treat. 2013 Jul;140(2):341-51. doi: 10.1007/s10549-013-2574-2. Epub 2013 Jul 23.

30.

BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.

D'Alfonso TM, van Laar RK, Vahdat LT, Hussain W, Flinchum R, Brown N, John LS, Shin SJ.

Breast Cancer Res Treat. 2013 Jun;139(3):705-15. doi: 10.1007/s10549-013-2604-0. Epub 2013 Jun 18.

PMID:
23774991
31.

High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.

Martz J, Jain S, Vahdat LT, Qin L, Mosquera JM, Antonescu CR, Popa EC.

J Clin Oncol. 2013 Apr 10;31(11):e181-5. doi: 10.1200/JCO.2012.42.7989. Epub 2013 Feb 25. No abstract available.

32.

Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.

Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Hurtado Rúa SM, Benkert S, Mathijsen Greenwood C, Zelkowitz R, Warren JD, Lane ME, Mittal V, Rafii S, Vahdat LT.

Ann Oncol. 2013 Jun;24(6):1491-8. doi: 10.1093/annonc/mds654. Epub 2013 Feb 13.

33.

Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.

Somlo G, Atzori F, Strauss LC, Geese WJ, Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT, Cortes J.

Clin Cancer Res. 2013 Apr 1;19(7):1884-93. doi: 10.1158/1078-0432.CCR-12-0652. Epub 2013 Feb 12.

34.

Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration.

Ryu S, McDonnell K, Choi H, Gao D, Hahn M, Joshi N, Park SM, Catena R, Do Y, Brazin J, Vahdat LT, Silver RB, Mittal V.

Cancer Cell. 2013 Jan 14;23(1):63-76. doi: 10.1016/j.ccr.2012.11.019.

35.

Microenvironmental regulation of epithelial-mesenchymal transitions in cancer.

Gao D, Vahdat LT, Wong S, Chang JC, Mittal V.

Cancer Res. 2012 Oct 1;72(19):4883-9. doi: 10.1158/0008-5472.CAN-12-1223. Epub 2012 Sep 20. Review.

36.

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.

Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, Fornier MN, Martín M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA.

Support Care Cancer. 2012 Nov;20(11):2661-8. doi: 10.1007/s00520-012-1384-0. Epub 2012 Mar 2.

37.

Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition.

Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, Port JL, Stiles B, Sukumar S, Altorki NK, Rafii S, Mittal V.

Cancer Res. 2012 Mar 15;72(6):1384-94. doi: 10.1158/0008-5472.CAN-11-2905. Epub 2012 Jan 26.

38.

The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.

Keir CH, Vahdat LT.

Expert Opin Biol Ther. 2012 Feb;12(2):259-63. doi: 10.1517/14712598.2012.642357. Epub 2012 Jan 9. Review.

PMID:
22229970
39.

Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.

Jain S, Ward MM, O'Loughlin J, Boeck M, Wiener N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Christos P, Baergen RN, Swistel A, Lane ME, Mittal V, Rafii S, Vahdat LT.

Breast Cancer Res Treat. 2012 Feb;132(1):235-42. doi: 10.1007/s10549-011-1906-3. Epub 2011 Dec 9.

40.

Employment after a breast cancer diagnosis: a qualitative study of ethnically diverse urban women.

Blinder VS, Murphy MM, Vahdat LT, Gold HT, de Melo-Martin I, Hayes MK, Scheff RJ, Chuang E, Moore A, Mazumdar M.

J Community Health. 2012 Aug;37(4):763-72. doi: 10.1007/s10900-011-9509-9.

PMID:
22109386
41.

Eribulin mesylate.

Jain S, Vahdat LT.

Clin Cancer Res. 2011 Nov 1;17(21):6615-22. doi: 10.1158/1078-0432.CCR-11-1807. Epub 2011 Aug 22. Review.

42.

Novel treatment options in the management of metastatic breast cancer.

Twelves C, Vahdat LT, Cortés J.

Clin Adv Hematol Oncol. 2011 May;9(5 Suppl 10):1-16. Review.

PMID:
21738118
43.

Breast cancer methylomes establish an epigenomic foundation for metastasis.

Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA.

Sci Transl Med. 2011 Mar 23;3(75):75ra25. doi: 10.1126/scitranslmed.3001875.

44.

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators.

Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2.

PMID:
21376385
45.

Treatment of metastatic breast cancer: second line and beyond.

Roché H, Vahdat LT.

Ann Oncol. 2011 May;22(5):1000-10. doi: 10.1093/annonc/mdq429. Epub 2010 Oct 21. Review.

PMID:
20966181
46.

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.

Morrow PK, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M, Schmelter T, Wang Y, Hortobagyi GN, Vahdat LT.

Breast Cancer Res Treat. 2010 Oct;123(3):837-42. doi: 10.1007/s10549-010-1102-x. Epub 2010 Aug 10.

PMID:
20697802
47.

The effect of a contemplative self-healing program on quality of life in women with breast and gynecologic cancers.

Loizzo JJ, Peterson JC, Charlson ME, Wolf EJ, Altemus M, Briggs WM, Vahdat LT, Caputo TA.

Altern Ther Health Med. 2010 May-Jun;16(3):30-7.

PMID:
20486622
48.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.

Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH.

Breast Cancer Res Treat. 2010 Jul;122(2):409-18. doi: 10.1007/s10549-010-0901-4. Epub 2010 May 8.

PMID:
20454927
49.

Eribulin mesylate for the treatment of breast cancer.

Cigler T, Vahdat LT.

Expert Opin Pharmacother. 2010 Jun;11(9):1587-93. doi: 10.1517/14656566.2010.486790. Review.

PMID:
20450446
50.

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.

Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA.

Clin Breast Cancer. 2010 Apr;10(2):160-3. doi: 10.3816/CBC.2010.n.023.

PMID:
20299316

Supplemental Content

Loading ...
Support Center